Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoART in HER2+ Esophagogastric Adenocarcinoma
NCT06731803Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Mar 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in Esophago-Gastric Adenocarcinoma (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Feasibility rate at 9 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Esophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on NCT06731803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06731803.